Journal
PHARMACEUTICALS
Volume 14, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/ph14030236
Keywords
proteases; NK cells; MHC; cathepsin G; immunotherapy
Categories
Funding
- Nazarbayev University Faculty-Development Competitive Research Grants Program [280720FD1907]
Ask authors/readers for more resources
The article summarizes the latest findings on how MHC I molecules affect NK cell surveillance of glioblastoma cells.
Immunotherapy has been established as an important area in the therapy of malignant diseases. Immunogenicity sufficient for immune recognition and subsequent elimination can be bypassed by tumors through altered and/or reduced expression levels of major histocompatibility complex class I (MHC I) molecules. Natural killer (NK) cells can eliminate tumor cells in a MHC I antigen presentation-independent manner by an array of activating and inhibitory receptors, which are promising candidates for immunotherapy. Here we summarize the latest findings in recognizing and regulating MHC I molecules that affect NK cell surveillance of glioblastoma cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available